癌症研究人口统计分析 优先事项和治疗相关性
Denis Horgan1,2, Marc Van den Bulcke3, Umberto Malapelle4
1European Alliance for Personalised Medicine, 1040 Brussels, Belgium.
Current oncology (Toronto, Ont.)
|April 26, 2024
概括
癌症研究重点因年龄而异,45-69岁患者的需求一致,70岁以上的老年患者有不同的需求. 治疗相关性突出显示了一种多学科的方法,以获得最佳的瘤治疗结果.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 公共卫生 公共卫生
背景情况:
- 了解癌症研究重点和治疗相关性对于不断发展的瘤学至关重要.
- 在UNCAN.eu倡议下与欧洲癌症患者联盟 (ECPC) 和儿童癌症国际-欧洲 (CCI-E) 合作.
研究的目的:
- 探索癌症研究中的人口统计数据,诊断以来的时间和治疗类型.
- 分析不同癌症治疗方法之间的相关性.
- 确定特定年龄和性别的癌症研究优先事项.
主要方法:
- 综合调查数据分析.
- 聚焦年龄和性别的人口统计分析.
- 癌症治疗类型的相关性分析 (手术,放射治疗,化疗,精密治疗,生物疗法).
主要成果:
- 年龄在45-69岁之间的个体表明癌症研究优先事项一致.
- 70岁以上的患者显示出不同的研究重点,表明了独特的需求.
- 手术,放射治疗,化疗,精密疗法和生物疗法之间的相互作用突出了多学科的方法.
结论:
- 癌症研究的优先事项和治疗相关性是复杂的,并且取决于背景.
- 一个多面的,以患者为中心的方法对于推进癌症研究和治疗至关重要.
- 持续的支持,适应和合作对于应对瘤学的动态环境至关重要.
更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.0K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
259
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Comparing the Survival Analysis of Two or More Groups
178
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
178
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer
48.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
48.5K
Hazard Ratio
115
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
115
